De Boer IH , Caramori ML , Chan JCN , Heerspink HJ , Hurst C , Khunti K , et al. ERA-EDTA Immunonephrology Working Group: Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment. Kidney Int 98: 839–848, 2020 PubMed
Fiorentino M , Bolignano D , Tesar V , Pisano A , Biesen WV , Tripepi G , et al.; ERA-EDTA Immunonephrology Working Group: Renal biopsy in patients with diabetes: A pooled meta-analysis of 48 studies. Nephrol Dial Transplant 32: 97–110, 2017 PubMed
Levey AS , Eckardt KU , Dorman NM , Christiansen SL , Hoorn EJ , Ingelfinger JR , et al.: Nomenclature for kidney function and disease: Report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int 97: 1117–1129, 2020 PubMed
Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England) 395: 709–733, 2020
Thomas B : The global burden of diabetic kidney disease: Time trends and gender gaps. Curr Diab Rep 19: 18, 2019 PubMed
Centers for Disease Control and Prevention: Chronic Kidney Disease Surveillance System—United States 2020 [cited 2020 6-23-2020]. Available from: http://www.cdc.gov/ckd.
Centers for Disease Control and Prevention: Chronic Kidney Disease Surveillance System 2019 [Available from: https://nccd.cdc.gov/CKD.
Saran R , Robinson B , Abbott KC , Bragg-Gresham J , Chen X , Gipson D , et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 75: A6–A7, 2020 PubMed
Bash LD , Coresh J , Köttgen A , Parekh RS , Fulop T , Wang Y , et al.: Defining incident chronic kidney disease in the research setting: The ARIC study. Am J Epidemiol 170: 414–424, 2009 PubMed
McCullough KP , Morgenstern H , Saran R , Herman WH , Robinson BM : Projecting ESRD incidence and prevalence in the United States through 2030. J Am Soc Nephrol 30: 127–135, 2019 PubMed
Narva A : Population health for CKD and diabetes: Lessons from the Indian Health Service. Am J Kidney Dis 71: 407–411, 2018 PubMed
Ríos Burrows N , Zhang Y , Hora I , Pavkov ME , Sheff K , Imperatore G , et al.: Sustained lower incidence of diabetes-related end-stage kidney disease among American Indians and Alaska Natives, Blacks, and Hispanics in the U.S., 2000-2016. Diabetes Care 43: 2090–2097, 2020 PubMed
Lamacchia O , Viazzi F , Fioretto P , Mirijello A , Giorda C , Ceriello A , et al.: Normoalbuminuric kidney impairment in patients with T1DM: Insights from annals initiative. Diabetol Metab Syndr 10: 60, 2018 PubMed
Doshi SM , Friedman AN : Diagnosis and management of type 2 diabetic kidney disease. Clin J Am Soc Nephrol 12: 1366–1373, 2017 PubMed
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease: Am J Kidney Dis 49[Suppl 2]: S12–S154, 2007 PubMed
Koye DN , Magliano DJ , Nelson RG , Pavkov ME : The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis 25: 121–132, 2018 PubMed
Comai G , Malvi D , Angeletti A , Vasuri F , Valente S , Ambrosi F , et al.: Histological evidence of diabetic kidney disease precede clinical diagnosis. Am J Nephrol 50: 29–36, 2019 PubMed
Tervaert TW , Mooyaart AL , Amann K , Cohen AH , Cook HT , Drachenberg CB , et al.; Renal Pathology Society: Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 21: 556–563, 2010 PubMed
Erdogmus S , Kiremitci S , Celebi ZK , Akturk S , Duman N , Ates K , et al.: Non-diabetic kidney disease in type 2 diabetic patients: Prevalence, clinical predictors and outcomes. Kidney Blood Press Res 42: 886–893, 2017 PubMed
Hogan JJ , Owen JG , Blady SJ , Almaani S , Avasare RS , Bansal S , et al.; TRIDENT Study Investigators: The feasibility and safety of obtaining research kidney biopsy cores in patients with diabetes: An interim analysis of the TRIDENT study. Clin J Am Soc Nephrol 15: 1024–1026, 2020 PubMed
Moledina DG , Cheung B , Kukova L , Luciano RL , Peixoto AJ , Wilson FP , et al.: A survey of patient attitudes toward participation in biopsy-based kidney research. Kidney Int Rep 3: 412–416, 2017 PubMed
Zeng C , Nan Y , Xu F , Lei Q , Li F , Chen T , et al.: Identification of glomerular lesions and intrinsic glomerular cell types in kidney diseases via deep learning. J Pathol 252: e5491, 2020 PubMed
Retnakaran R , Cull CA , Thorne KI , Adler AI , Holman RR ; UKPDS Study Group: Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 55: 1832–1839, 2006 PubMed
Krolewski AS : Progressive renal decline: The new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care 38: 954–962, 2015 PubMed
Colhoun HM , Marcovecchio ML : Biomarkers of diabetic kidney disease. Diabetologia 61: 996–1011, 2018 PubMed
Coca SG , Nadkarni GN , Huang Y , Moledina DG , Rao V , Zhang J , et al.: Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J Am Soc Nephrol 28: 2786–2793, 2017 PubMed
Zhou LT , Lv LL , Liu BC : Urinary biomarkers of renal fibrosis. Adv Exp Med Biol 1165: 607–623, 2019 PubMed
Pontillo C , Mischak H : Urinary peptide-based classifier CKD273: Towards clinical application in chronic kidney disease. Clin Kidney J 10: 192–201, 2017 PubMed
Nkuipou-Kenfack E , Zürbig P , Mischak H : The long path towards implementation of clinical proteomics: Exemplified based on CKD273. Proteomics Clin Appl 11: 2017 PubMed
Lindhardt M , Persson F , Zürbig P , Stalmach A , Mischak H , de Zeeuw D , et al.: Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. Nephrol Dial Transplant 32: 1866–1873, 2017 PubMed
Tofte N , Lindhardt M , Adamova K , Bakker SJL , Beige J , Beulens JWJ , et al.; PRIORITY investigators: Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): A prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol 8: 301–312, 2020 PubMed
Looker HC , Mauer M , Nelson RG : Role of kidney biopsies for biomarker discovery in diabetic kidney disease. Adv Chronic Kidney Dis 25: 192–201, 2018 PubMed
Stevens PE , Levin A ; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members: Evaluation and management of chronic kidney disease: synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158: 825–830, 2013 PubMed
Adler AI , Stevens RJ , Manley SE , Bilous RW , Cull CA , Holman RR ; UKPDS GROUP: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63: 225–232, 2003 PubMed
Koye DN , Shaw JE , Reid CM , Atkins RC , Reutens AT , Magliano DJ : Incidence of chronic kidney disease among people with diabetes: A systematic review of observational studies. Diabet Med 34: 887–901, 2017 PubMed
Levin A , Stevens PE : Summary of KDIGO 2012 CKD Guideline: Behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 85: 49–61, 2014 PubMed
Nichols GA , Déruaz-Luyet A , Brodovicz KG , Kimes TM , Rosales AG , Hauske SJ : Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with versus without type 2 diabetes. BMC Nephrol 21: 167, 2020 PubMed
National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases: United States Renal Data System. 2019 USRDS annual data report: Epidemiology of kidney disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2019
Sumida K , Nadkarni GN , Grams ME , Sang Y , Ballew SH , Coresh J , et al.: Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: An individual participant-based meta-analysis. Ann Intern Med 173: 425–435, 202014 PubMed
Tuttle KR , Alicic RZ , Duru OK , Jones CR , Daratha KB , Nicholas SB , et al.: Clinical characteristics of and risk factors for chronic kidney disease among adults and children: An analysis of the CURE-CKD registry. JAMA Netw Open 2: e1918169, 2019 PubMed
Radcliffe NJ , Seah JM , Clarke M , MacIsaac RJ , Jerums G , Ekinci EI : Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig 8: 6–18, 2017 PubMed
Elley CR , Robinson T , Moyes SA , Kenealy T , Collins J , Robinson E , et al.: Derivation and validation of a renal risk score for people with type 2 diabetes. Diabetes Care 36: 3113–3120, 2013 PubMed
Low S , Lim SC , Zhang X , Zhou S , Yeoh LY , Liu YL , et al.: Development and validation of a predictive model for chronic kidney disease progression in type 2 diabetes mellitus based on a 13-year study in Singapore. Diabetes Res Clin Pract 123: 49–54, 2017 PubMed
Tangri N , Stevens LA , Griffith J , Tighiouart H , Djurdjev O , Naimark D , et al.: A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305: 1553–1559, 2011 PubMed
Tangri N , Grams ME , Levey AS , Coresh J , Appel LJ , Astor BC , et al.; CKD Prognosis Consortium: Multinational assessment of accuracy of equations for predicting risk of kidney failure: A meta-analysis. JAMA 315: 164–174, 2016 PubMed
Nelson RG , Grams ME , Ballew SH , Sang Y , Azizi F , Chadban SJ , et al.; CKD Prognosis Consortium: Development of risk prediction equations for incident chronic kidney disease. JAMA 322: 2104–2114, 2019 PubMed
Mise K , Hoshino J , Ueno T , Hazue R , Sumida K , Hiramatsu R , et al.: Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy. Diabetes Metab Res Rev 31: 572–581, 2015 PubMed
Fufaa GD , Weil EJ , Lemley KV , Knowler WC , Brosius FC 3rd , Yee B , et al.: Structural predictors of loss of renal function in American Indians with type 2 diabetes. Clin J Am Soc Nephrol 11: 254–261, 2016 PubMed
Nicholas SB : Structural Predictors of Renal Function Decline. Clin J Am Soc Nephrol 11: 202–204, 2016 PubMed
Yamanouchi M , Hoshino J , Ubara Y , Takaichi K , Kinowaki K , Fujii T , et al.: Value of adding the renal pathological score to the kidney failure risk equation in advanced diabetic nephropathy. PLoS One 13: e0190930, 2018 PubMed
Sun L , Shang J , Xiao J , Zhao Z : Development and validation of a predictive model for end-stage renal disease risk in patients with diabetic nephropathy confirmed by renal biopsy. PeerJ 8: e8499, 2020 PubMed
Helal I , Fick-Brosnahan GM , Reed-Gitomer B , Schrier RW : Glomerular hyperfiltration: Definitions, mechanisms and clinical implications. Nat Rev Nephrol 8: 293–300, 2012 PubMed
Trevisan R , Dodesini AR : The Hyperfiltering Kidney in Diabetes. Nephron 136: 277–280, 2017 PubMed
Hostetter TH , Troy JL , Brenner BM : Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 19: 410–415, 1981 PubMed
Anderson S , Brenner BM . The role of intraglomerular pressure in the initiation and progression of renal disease. J Hypertens Suppl 4: S236–S238, 1986 PubMed
Anderson S , Brenner BM : Therapeutic benefit of converting-enzyme inhibition in progressive renal disease. Am J Hypertens 1: 380S–383S, 1988 PubMed
Zatz R , Dunn BR , Meyer TW , Anderson S , Rennke HG , Brenner BM : Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925–1930, 1986 PubMed
Hostetter TH , Olson JL , Rennke HG , Venkatachalam MA , Brenner BM : Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 241: F85–F93, 1981 PubMed
Brenner BM , Meyer TW , Hostetter TH : Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307: 652–659, 1982 PubMed
Grabias BM , Konstantopoulos K : The physical basis of renal fibrosis: Effects of altered hydrodynamic forces on kidney homeostasis. Am J Physiol Renal Physiol 306: F473–F485, 2014 PubMed
Hostetter TH , Rennke HG , Brenner BM : The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72: 375–380, 1982 PubMed
Premaratne E , Verma S , Ekinci EI , Theverkalam G , Jerums G , MacIsaac RJ : The impact of hyperfiltration on the diabetic kidney. Diabetes Metab 41: 5–17, 2015 PubMed
Tuttle KR , Bruton JL : Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. Kidney Int 42: 167–173, 1992 PubMed
Tuttle KR , Bruton JL , Perusek MC , Lancaster JL , Kopp DT , DeFronzo RA : Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 324: 1626–1632, 1991 PubMed
Tuttle KR , Puhlman ME , Cooney SK , Short RA : Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes. Am J Physiol Renal Physiol 282: F103–F112, 2002 PubMed
Heerspink HJ , Perkins BA , Fitchett DH , Husain M , Cherney DZ : Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134: 752–772, 2016 PubMed
Tuttle KR : Back to the future: Glomerular hyperfiltration and the diabetic kidney. Diabetes 66: 14–16, 2017 PubMed
Alicic RZ , Rooney MT , Tuttle KR : Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol 12: 2032–2045, 2017 PubMed
Vallon V , Komers R : Pathophysiology of the diabetic kidney. Compr Physiol 1: 1175–1232, 2011 PubMed
Brenner BM , Lawler EV , Mackenzie HS : The hyperfiltration theory: A paradigm shift in nephrology. Kidney Int 49: 1774–1777, 1996 PubMed
Tonneijck L , Muskiet MH , Smits MM , van Bommel EJ , Heerspink HJ , van Raalte DH , et al.: Glomerular hyperfiltration in diabetes: Mechanisms, clinical significance, and treatment. J Am Soc Nephrol 28: 1023–1039, 2017 PubMed
Penno G , Orsi E , Solini A , Bonora E , Fondelli C , Trevisan R , et al.; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group: Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: A prospective cohort study. BMJ Open Diabetes Res Care 8: e001481, 2020 PubMed
Reboldi G , Verdecchia P , Fiorucci G , Beilin LJ , Eguchi K , Imai Y , et al.: Glomerular hyperfiltration is a predictor of adverse cardiovascular outcomes. Kidney Int 93: 195–203, 2018 PubMed
Zhao L , Zou Y , Liu F : Transforming growth factor-beta1 in diabetic kidney disease. Front Cell Dev Biol 8: 187, 2020 PubMed
Ying Q , Wu G : Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: An update. Ren Fail 39: 474–483, 2017 PubMed
Alicic RZ , Johnson EJ , Tuttle KR : Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease. Adv Chronic Kidney Dis 25: 181–191, 2018 PubMed
Pichler R , Afkarian M , Dieter BP , Tuttle KR : Immunity and inflammation in diabetic kidney disease: Translating mechanisms to biomarkers and treatment targets. Am J Physiol Renal Physiol 312: F716–F731, 2017 PubMed
Pérez-Morales RE , Del Pino MD , Valdivielso JM , Ortiz A , Mora-Fernández C , Navarro-González JF : Inflammation in diabetic kidney disease. Nephron 143: 12–16, 2019 PubMed
Oak JH , Cai H : Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 56: 118–126, 2007 PubMed
Turkmen K : Inflammation, oxidative stress, apoptosis, and autophagy in diabetes mellitus and diabetic kidney disease: The Four Horsemen of the Apocalypse. Int Urol Nephrol 49: 837–844, 2017 PubMed
Lin TA , Wu VC , Wang CY : Autophagy in chronic kidney diseases. Cells 8: 61, 2019 PubMed
Xin W , Li Z , Xu Y , Yu Y , Zhou Q , Chen L , et al.: Autophagy protects human podocytes from high glucose-induced injury by preventing insulin resistance. Metabolism 65: 1307–1315, 2016 PubMed
Zeni L , Norden AGW , Cancarini G , Unwin RJ : A more tubulocentric view of diabetic kidney disease. J Nephrol 30: 701–717, 2017 PubMed
Wang Z , do Carmo JM , da Silva AA , Fu Y , Hall JE : Mechanisms of synergistic interactions of diabetes and hypertension in chronic kidney disease: Role of mitochondrial dysfunction and ER stress. Curr Hypertens Rep 22: 15, 2020 PubMed
Yang S , Han Y , Liu J , Song P , Xu X , Zhao L , et al.: Mitochondria: A novel therapeutic target in diabetic nephropathy. Curr Med Chem 24: 3185–3202, 2017 PubMed
Kobayashi M , Yamamoto M : Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul 46: 113–140, 2006 PubMed
Abdel-Salam OM , Baiuomy AR , El-Shenawy SM , Arbid MS : The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat. Pharmacol Res 47: 331–340, 2003 PubMed
Navarro-González JF , Mora-Fernández C , Muros de Fuentes M , Chahin J , Méndez ML , Gallego E , et al.: Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: The PREDIAN trial. J Am Soc Nephrol 26: 220–229, 2015 PubMed
Scheele W , Diamond S , Gale J , Clerin V , Tamimi N , Le V , et al.: Phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy. J Am Soc Nephrol 27: 3459–3468, 2016 PubMed
Musah S , Mammoto A , Ferrante TC , Jeanty SSF , Hirano-Kobayashi M , Mammoto T , et al.: Mature induced-pluripotent-stem-cell-derived human podocytes reconstitute kidney glomerular-capillary-wall function on a chip. Nat Biomed Eng 1: 0069, 2017 PubMed
Petrosyan A , Cravedi P , Villani V , Angeletti A , Manrique J , Renieri A , et al.: A glomerulus-on-a-chip to recapitulate the human glomerular filtration barrier. Nat Commun 10: 3656, 2019 PubMed
Musah S , Dimitrakakis N , Camacho DM , Church GM , Ingber DE : Directed differentiation of human induced pluripotent stem cells into mature kidney podocytes and establishment of a glomerulus chip. Nat Protoc 13: 1662–1685, 2018 PubMed
Seaquist ER , Goetz FC , Rich S , Barbosa J : Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320: 1161–1165, 1989 PubMed
Borch-Johnsen K , Nørgaard K , Hommel E , Mathiesen ER , Jensen JS , Deckert T , et al.: Is diabetic nephropathy an inherited complication? Kidney Int 41: 719–722, 1992 PubMed
Freedman BI , Tuttle AB , Spray BJ : Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis 25: 710–713, 1995 PubMed
Pettitt DJ , Saad MF , Bennett PH , Nelson RG , Knowler WC : Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33: 438–443, 1990 PubMed
International HapMap Consortium: A haplotype map of the human genome. Nature 437: 1299–1320, 2005 PubMed
Schelling JR , Abboud HE , Nicholas SB , Pahl MV , Sedor JR , Adler SG , et al.; Family Investigation of Nephropathy and Diabetes Research Group: Genome-wide scan for estimated glomerular filtration rate in multi-ethnic diabetic populations: The Family Investigation of Nephropathy and Diabetes (FIND). Diabetes 57: 235–243, 2008 PubMed
Iyengar SK , Sedor JR , Freedman BI , Kao WH , Kretzler M , Keller BJ , et al.; Family Investigation of Nephropathy and Diabetes (FIND): Genome-wide association and trans-ethnic meta-analysis for advanced diabetic kidney disease: Family investigation of nephropathy and diabetes (FIND). PLoS Genet 11: e1005352, 2015 PubMed
Iyengar SK , Abboud HE , Goddard KA , Saad MF , Adler SG , Arar NH , et al.; Family Investigation of Nephropathy and Diabetes Research Group: Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: The family investigation of nephropathy and diabetes (FIND). Diabetes 56: 1577–1585, 2007 PubMed
van Zuydam NR , Ahlqvist E , Sandholm N , Deshmukh H , Rayner NW , Abdalla M , et al.; Finnish Diabetic Nephropathy Study (FinnDiane); Hong Kong Diabetes Registry Theme-based Research Scheme Project Group; Warren 3 and Genetics of Kidneys in Diabetes (GoKinD) Study Group; GENIE (GEnetics of Nephropathy an International Effort) Consortium; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group; SUrrogate markers for Micro- and Macrovascular hard endpoints for Innovative diabetes Tools (SUMMIT) Consortium: A genome-wide association study of diabetic kidney disease in subjects with type 2 diabetes. Diabetes 67: 1414–1427, 2018 PubMed
Gu HF : Genetic and epigenetic studies in diabetic kidney disease. Front Genet 10: 507, 2019 PubMed
Li M , Pezzolesi MG : Advances in understanding the genetic basis of diabetic kidney disease. Acta Diabetol 55: 1093–1104, 2018 PubMed
Berger SL , Kouzarides T , Shiekhattar R , Shilatifard A : An operational definition of epigenetics. Genes Dev 23: 781–783, 2009 PubMed
Stumvoll M : Glucose production by the human kidney--its importance has been underestimated. Nephrol Dial Transplant 13: 2996–2999, 1998 PubMed
Gan T , Liu X , Xu G : Glycated albumin versus HbA1c in the evaluation of glycemic control in patients with diabetes and CKD. Kidney Int Rep 3: 542–554, 2017 PubMed
Pham H , Robinson-Cohen C , Biggs ML , Ix JH , Mukamal KJ , Fried LF , et al.: Chronic kidney disease, insulin resistance, and incident diabetes in older adults. Clin J Am Soc Nephrol 7: 588–594, 2012 PubMed
Coca SG , Ismail-Beigi F , Haq N , Krumholz HM , Parikh CR : Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: Systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 172: 761–769, 2012 PubMed
Kelly TN , Bazzano LA , Fonseca VA , Thethi TK , Reynolds K , He J : Systematic review: Glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 151: 394–403, 2009 PubMed
Galindo RJ , Beck RW , Scioscia MF , Umpierrez GE , Tuttle KR : Glycemic monitoring and management in advanced chronic kidney disease. Endocr Rev 41: 756–774, 2020 PubMed
Wong MG , Perkovic V , Chalmers J , Woodward M , Li Q , Cooper ME , et al.; ADVANCE-ON Collaborative Group: Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39: 694–700, 2016 PubMed
Tuttle KR , McGill JB : Evidence-based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease. Diabetes Obes Metab 22: 1014–1023, 2020 PubMed
Ruospo M , Saglimbene VM , Palmer SC , De Cosmo S , Pacilli A , Lamacchia O , et al.: Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev 6: CD010137, 2017 PubMed
Zoungas S , Arima H , Gerstein HC , Holman RR , Woodward M , Reaven P , et al.; Collaborators on Trials of Lowering Glucose (CONTROL) group: Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: A meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 5: 431–437, 2017 PubMed
Freedman BI , Shihabi ZK , Andries L , Cardona CY , Peacock TP , Byers JR , et al.: Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am J Nephrol 31: 375–379, 2010 PubMed
Ichikawa H , Nagake Y , Takahashi M , Nakazono H , Kawabata K , Shikata K , et al..: What is the best index of glycemic control in patient with diabetes mellitus on hemodialysis? Nihon Jinzo Gakkai Shi 38: 305–308, 1996 PubMed
García-Carro C , Vergara A , Agraz I , Jacobs-Cachá C , Espinel E , Seron D , et al.: The new era for reno-cardiovascular treatment in type 2 diabetes. J Clin Med 8: 864, 2019 PubMed
Cornell S : Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE. J Am Pharm Assoc (2003) 57: 261–265, 2017 PubMed
Davies MJ , D’Alessio DA , Fradkin J , Kernan WN , Mathieu C , Mingrone G , et al.: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41: 2669–2701, 2018 PubMed
Maruthur NM , Tseng E , Hutfless S , Wilson LM , Suarez-Cuervo C , Berger Z , et al.: Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med 164: 740–751, 2016 PubMed
Jasim S , Smith SA : Review: Metformin is linked to reduced mortality in type 2 diabetes with comorbid CKD and CHF. Ann Intern Med 166: JC46, 2017 PubMed
Crowley MJ , Diamantidis CJ , McDuffie JR , Cameron CB , Stanifer JW , Mock CK , et al.: Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: A systematic review. Ann Intern Med 166: 191–200, 2017 PubMed
Prabhu RA , Mareddy AS , Nagaraju SP , Rangaswamy D , Guddattu V : Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3-5: Is it significant? Int Urol Nephrol 51: 1229–1230, 2019 PubMed
Thomson SC , Vallon V . SGLT2 Renal effects of sodium-glucose co-transporter inhibitors. Am J Cardiol 124: S28–S35, 2019 PubMed
Cowie MR , Fisher M : SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control [published online ahead of print Jul 14, 2020]. Nat Rev Cardiol doi: 10.1038/s41569-020-0406-8. 2020 PubMed
Markham A : Ertugliflozin: First Global Approval. Drugs 78: 513–519, 2018 PubMed
Aronson R , Frias J , Goldman A , Darekar A , Lauring B , Terra SG : Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab 20: 1453–1460, 2018 PubMed
National Kidney Foundation. KDIGO clinical practice guidelines on diabetes management iin chronic kidney disease Available at: https://kdigo.org/guidelines/diabetes-ckd/. Accessed October 19, 2020
Zinman B , Wanner C , Lachin JM , Fitchett D , Bluhmki E , Hantel S , et al.; EMPA-REG OUTCOME Investigators: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117–2128, 2015 PubMed
Neal B , Perkovic V , Mahaffey KW , de Zeeuw D , Fulcher G , Erondu N , et al.; CANVAS Program Collaborative Group: Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644–657, 2017 PubMed
Wiviott SD , Raz I , Bonaca MP , Mosenzon O , Kato ET , Cahn A , et al.; DECLARE–TIMI 58 Investigators: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380: 347–357, 2019 PubMed
Perkovic V , Jardine MJ , Neal B , Bompoint S , Heerspink HJL , Charytan DM , et al.; CREDENCE Trial Investigators: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380: 2295–2306, 2019 PubMed
Heerspink HJL , Stefansson BV , Correa-Rotter R , Chertow GM , Greene T , Hou FF , et al.; Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383: 1436–1446, 2020 PubMed
McMurray JJV , Solomon SD , Inzucchi SE , Køber L , Kosiborod MN , Martinez FA , et al.; DAPA-HF Trial Committees and Investigators: Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381: 1995–2008, 2019 PubMed
Kosiborod M , Cavender MA , Fu AZ , Wilding JP , Khunti K , Holl RW , et al.; CVD-REAL Investigators and Study Group*: Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation 136: 249–259, 2017 PubMed
Patorno E , Pawar A , Franklin JM , Najafzadeh M , Déruaz-Luyet A , Brodovicz KG , et al.: Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation 139: 2822–2830, 2019 PubMed
McLachlan G , Keith C , Frauman A . Diabetic ketoacidosis with sodium-glucose transporter type 2 inhibitors: A case series. Med J Aust 211: 237–237.e1, 2019 PubMed
Fadini GP , Bonora BM , Avogaro A : SGLT2 inhibitors and diabetic ketoacidosis: Data from the FDA Adverse Event Reporting System. Diabetologia 60: 1385–1389, 2017 PubMed
Danne T , Garg S , Peters AL , Buse JB , Mathieu C , Pettus JH , et al.: International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 42: 1147–1154, 2019 PubMed
Puckrin R , Saltiel MP , Reynier P , Azoulay L , Yu OHY , Filion KB : SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 55: 503–514, 2018 PubMed
Yabe D , Yasui A , Ji L , Lee MK , Ma RCW , Chang TJ , et al.: Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials. J Diabetes Investig 10: 418–428, 2019 PubMed
Muskiet MHA , Tonneijck L , Smits MM , van Baar MJB , Kramer MHH , Hoorn EJ , et al.: GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol 13: 605–628, 2017 PubMed
Gerstein HC , Colhoun HM , Dagenais GR , Diaz R , Lakshmanan M , Pais P , et al.; REWIND Investigators: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet 394: 121–130, 2019 PubMed
Marso SP , Bain SC , Consoli A , Eliaschewitz FG , Jódar E , Leiter LA , et al.; SUSTAIN-6 Investigators: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375: 1834–1844, 2016 PubMed
Marso SP , Daniels GH , Brown-Frandsen K , Kristensen P , Mann JF , Nauck MA , et al.; LEADER Steering Committee; LEADER Trial Investigators: Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375: 311–322, 2016 PubMed
Gerstein HC , Colhoun HM , Dagenais GR , Diaz R , Lakshmanan M , Pais P , et al.; REWIND Investigators: Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394: 131–138, 2019 PubMed
Bridoux F , Carron PL , Pegourie B , Alamartine E , Augeul-Meunier K , Karras A , et al.; MYRE Study Group: Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: A randomized clinical trial. JAMA 318: 2099–2110, 2017 PubMed
Husain M , Birkenfeld AL , Donsmark M , Dungan K , Eliaschewitz FG , Franco DR , et al.; PIONEER 6 Investigators: Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381: 841–851, 2019 PubMed
Tuttle KR , Lakshmanan MC , Rayner B , Busch RS , Zimmermann AG , Woodward DB , et al.: Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6: 605–617, 2018 PubMed
Tuttle KR , Rayner B , Lakshmanan M , Woodward B , Kwan A , Konig M , et al.: Clinical events in type 2 diabetes and moderate-to-severe CKD by albuminuria status: Dulaglutide versus insulin glargine. J Am Soc Nephrol Abstract Supplement. 30: 102, 2019
Buse JB , Wexler DJ , Tsapas A , Rossing P , Mingrone G , Mathieu C , et al.: 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43: 487–493, 2020 PubMed
Coats AJS , Seferović PM : News from the American Heart Association: More on sodium-glucose co-transporter 2 inhibitors, diabetes and heart failure. Eur J Heart Fail 21: 261–263, 2019 PubMed
Das SR , Everett BM , Birtcher KK , Brown JM , Januzzi JL Jr , Kalyani RR , et al.: 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 76: 1117–1145, 2020 PubMed
Cheng M , Gu X , Turbat-Herrera EA , Herrera GA : Tubular injury and dendritic cell activation are integral components of light chain-associated acute tubulointerstitial nephritis. Arch Pathol Lab Med 143: 1212–1224, 2019 PubMed
Mosenzon O , Leibowitz G , Bhatt DL , Cahn A , Hirshberg B , Wei C , et al.: Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care 40: 69–76, 2017 PubMed
Cornel JH , Bakris GL , Stevens SR , Alvarsson M , Bax WA , Chuang LM , et al.; TECOS Study Group: Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS. Diabetes Care 39: 2304–2310, 2016 PubMed
Rosenstock J , Perkovic V , Johansen OE , Cooper ME , Kahn SE , Marx N , et al.; CARMELINA Investigators: Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA 321: 69–79, 2019 PubMed
UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703–713, 1998 PubMed
Papademetriou V , Zaheer M , Doumas M , Lovato L , Applegate WB , Tsioufis C , et al.; ACCORD Study Group: Cardiovascular outcomes in action to control cardiovascular risk in diabetes: Impact of blood pressure level and presence of kidney disease. Am J Nephrol 43: 271–280, 2016 PubMed
Cushman WC , Evans GW , Byington RP , Goff DC Jr , Grimm RH Jr , Cutler JA , et al.; ACCORD Study Group: Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362: 1575–1585, 2010 PubMed
Bakris GL , Weir MR , Shanifar S , Zhang Z , Douglas J , van Dijk DJ , et al.; RENAAL Study Group: Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study. Arch Intern Med 163: 1555–1565, 2003 PubMed
Berl T , Hunsicker LG , Lewis JB , Pfeffer MA , Porush JG , Rouleau JL , et al.; Collaborative Study Group: Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 16: 2170–2179, 2005 PubMed
Cooper-DeHoff RM , Gong Y , Handberg EM , Bavry AA , Denardo SJ , Bakris GL , et al.: Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304: 61–68, 2010 PubMed
Beddhu S , Greene T , Boucher R , Cushman WC , Wei G , Stoddard G , et al.: Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. Lancet Diabetes Endocrinol 6: 555–563, 2018 PubMed
Breyer JA , Bain RP , Evans JK , Nahman NS Jr , Lewis EJ , Cooper M , et al.; The Collaborative Study Group: Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 50: 1651–1658, 1996 PubMed
Pohl MA , Blumenthal S , Cordonnier DJ , De Alvaro F , Deferrari G , Eisner G , et al.: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations. J Am Soc Nephrol 16: 3027–3037, 2005 PubMed
Inker LA , Astor BC , Fox CH , Isakova T , Lash JP , Peralta CA , et al.: KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63: 713–735, 2014 PubMed
Strippoli GF , Bonifati C , Craig M , Navaneethan SD , Craig JC : Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006: CD006257, 2006 PubMed
Leehey DJ , Zhang JH , Emanuele NV , Whaley-Connell A , Palevsky PM , Reilly RF , et al.; VA NEPHRON-D Study Group: BP and renal outcomes in diabetic kidney disease: The Veterans Affairs nephropathy in diabetes trial. Clin J Am Soc Nephrol 10: 2159–2169, 2015 PubMed
Jhund PS , McMurray JJ , Chaturvedi N , Brunel P , Desai AS , Finn PV , et al.: Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. Eur Heart J 36: 2463–2469, 2015 PubMed
Othman SS , Austin PC , Tu JV , Lee DS : Effect of prepublication results on trends in prescribing of antihypertensive medication: Impact of the ALTITUDE (aliskiren trial in type 2 diabetes using cardio-renal disease endpoints) trial on aliskiren prescribing. Circ Cardiovasc Qual Outcomes 10: e003152, 2017 PubMed
Kalantar-Zadeh K , Joshi S , Schlueter R , Cooke J , Brown-Tortorici A , Donnelly M , et al.: Plant-dominant low-protein diet for conservative management of chronic kidney disease [published online ahead of print Jun 29, 2020]. Nutrients doi: 10.3390/nu12071031 PubMed
Ko GJ , Kalantar-Zadeh K , Goldstein-Fuchs J , Rhee CM : Dietary approaches in the management of diabetic patients with kidney disease. Nutrients 9: 824, 2017 PubMed
Kanauchi N , Ookawara S , Ito K , Mogi S , Yoshida I , Kakei M , et al.: Factors affecting the progression of renal dysfunction and the importance of salt restriction in patients with type 2 diabetic kidney disease. Clin Exp Nephrol 19: 1120–1126, 2015 PubMed
Ikizler TA , Robinson-Cohen C , Ellis C , Headley SAE , Tuttle K , Wood RJ , et al.: Metabolic effects of diet and exercise in patients with moderate to severe CKD: A randomized clinical trial. J Am Soc Nephrol 29: 250–259, 2018 PubMed
Yaribeygi H , Atkin SL , Simental-Mendía LE , Sahebkar A : Molecular mechanisms by which aerobic exercise induces insulin sensitivity. J Cell Physiol 234: 12385–12392, 2019 PubMed
Arnett DK , Khera A , Blumenthal RS : 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Part 1, lifestyle and behavioral factors. JAMA Cardiol 4: 1043–1044, 2019 PubMed
Feodoroff M , Harjutsalo V , Forsblom C , Thorn L , Wadén J , Tolonen N , et al.: Smoking and progression of diabetic nephropathy in patients with type 1 diabetes. Acta Diabetol 53: 525–533, 2016 PubMed
Ohkuma T , Nakamura U , Iwase M , Ide H , Fujii H , Jodai T , et al..: Effects of smoking and its cessation on creatinine- and cystatin C-based estimated glomerular filtration rates and albuminuria in male in patients with type 2 diabetes mellitus: The Fukuoka Diabetes Registry. Hypertens Res 39: 744–751, 2016 PubMed
Alicic RZ , Tuttle KR : Novel therapies for diabetic kidney disease. Adv Chronic Kidney Dis 21: 121–133, 2014 PubMed
Bakris GL , Agarwal R , Anker SD , Pitt B , Ruilope LM , Nowack C , et al.; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators: Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol 50: 333–344, 2019 PubMed
Doria A , Galecki AT , Spino C , Pop-Busui R , Cherney DZ , Lingvay I , et al.; PERL Study Group: Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med 382: 2493–2503, 2020 PubMed
Lytvyn Y , Godoy LC , Scholtes